Epidemiology of primary liver cancer

Seminars in Liver Disease

Volumn 19, Issue 3, 1999, Pages 271-285

  Bosch, F Xavier ^a   Ribes, Josepa ^a   Borràs, Joan ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Epidemiology; Liver cancer

Indexed keywords

AFLATOXIN;

ARTICLE; CANCER INCIDENCE; DEVELOPING COUNTRY; ETHNIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; LIVER CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032833628     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007117     Document Type: Article

References (101)

1. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents, vol. VII. Lyon: IARC Scientific Publications, No. 143, 1997
2. Parkin DM, Muir CS, Whelan SL, et al. Cancer incidence in five continents, vol. VI. Lyon: IARC Scientific Publications, No. 120, 1992
3. WHO Mortality Database. World Health Statistics Annuals. Available on the Internet (www-dep.iarc.fr)
4. Ferlay J, Parkin DM, Pisani P. GLOBOCAN graphical package 1: Cancer incidence and mortality worldwide. Lyon: IARC Press, 1998
5. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of twenty-five major cancers in 1990. Int J Cancer 1999;80:827-841
6. Parkin DM, Srivatanakul P, Khlat M, et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991;48:323-328
7. Junshi C, Campbell TC, Junyao L, et al. (eds) Diet, life-style and mortality in China. A study of the characteristics of 65 Chinese counties. Oxford: Oxford University Press, 1990
8. Hsing AW, Guo W, Chen J, et al. Correlates of liver cancer mortality in China. Int J Epidemiol 1991;20:54-59
9. Rosenblatt KA, Weiss NS, Schwartz SM. Liver cancer in Asian migrants to the United States and their descendants. Cancer, Causes, Control 1996;7(3):345-350
10. International Classification of Diseases, adapted for use in the United States, 8th rev. Washington, DC: Department of Health, Education and Welfare: Public Health Service Publication No. 1693, 1967
11. International Classification of Diseases, 9th rev., Clinical Modification. Washington, DC: Department of Health and Human Services (DHHS No. (PHS) 80-1260), 1979
12. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality of 25 cancers in 1990. Int J Cancer 1999;80:827-841
13. Okuda K, Fujimoto I, Hanai A, et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-4972
14. Okuda K. 9, Hepatitis C virus and hepatocellular carcinoma. In: Tabor E, Di Bisceglie AM, Purcell RH, (eds). Etiology, pathology, and treatment of hepatocellular carcinoma in North America. Houston: PPC-Gulf Publishing Company, 1991
15. Makimoto K, Higuchi S. Alcohol consumption as a major risk factor for the rise in liver cancer mortality rates in Japanese men. Int J of Epidemiol 1999;28:30-34
16. Hashem B, El-Serag, Andrew CM. Rising Incidence of Hepatocellular Carcinoma in the United States. N Engl J Med 1999; 340(10):745-750
17. Benhamiche AM, Faivre C, Minello A, et al. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J Hepatol 1998;29(5):802-806
18. De Vos Irvine H, Goldberg D, Hole DJ, et al. Trends in primary liver cancer (letter). Lancet 1998;351(9097):215-216
19. Lee HS, Han CJ, Kim CY. Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis B-endemic area. Cancer 1993;72:2564-2567
20. Bosch XB. 2, Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E (eds). Liver Cancer. London: Churchill Livingstone, 1997, 13-28
21. Tanaka K, Hirohata T, Fukuda K, et al. Risk factors for hepatocellular carcinoma among Japanese women. Cancer, Causes Control 1995;6:91-98
22. Wild CP, Hall AJ. Hepatitis B virus and liver cancer: Unanswered questions. In: Cancer Survey S, Volume 33: Infections and Human Cancer. Cold Spring Harbor, NY:CHSL Press, 1999
23. Tabor E. 8, Viral hepatitis and liver cancer. In: Goldin RD, Thomas HC, Gerber MA (eds). Viral Pathology of Viral hepatitis. London: Arnold, 1998, pp 161-177
24. Di Bisceglie AM, Carithers RL, Gores GJ. Hepatocellular carcinoma. Hepatalogy 1998;28:1161-1165
25. IARC. Hepatitis viruses, Vol 59. IARC Monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC Scientific Publications, International Agency for Research on Cancer, 1994
26. Donato F, Boffeta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354
27. Pisani P, Parkin DM, Muñoz N, et al. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol Biomark Prev 1997;6:387-400
28. WHO. Expanded programme on immunization. Hepatitis B vaccine. Update October 1996. Available on the Internet (www. who.int/gpv-surv/graphics/htmls/hepbprev.htm)
29. WHO. Hepatitis C. global prevalence. Weekly Epidemiological Record. No. 46. World Health Organization 1997;72:341-348
30. Pessoa MG, Terrault NA, Detmer J, et al. Quantitation of hepatitis G and C viruses in the liver: Evidence that hepatitis G virus is not hepatotropic. Hepatology 1998;27:877-880
31. Kao JH, Chen PJ, Lai MY, et al. GB virus-C/hepatitis G virus infection in an area endemic for viral hepatitis, chronic liver disease and liver cancer. Gastroenterology 1997;112:1265-1270
32. Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997;336:747-754
33. Alter MJ, Gallgher M, Morris TT, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 1997;336:741-746
34. Tagger A, Donato F, Ribero ML, et al. A case-control study in GB virus C/Hepatitis G virus infection and hepatocellular carcinoma. Hepatology 1997;26:1653-1657
35. Cao K, Mizokami M, Orito E, et al. GB virus C/hepatitis G virus infection among patients with hepatocellular carcinoma in the inshore area of the Yangtze River, China. J Gastroenterol Hepatol 1998;13(12):1241-1248
36. Paterlini P, Gerken G, Nakajima E, et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med 1990;323:80-85
37. Bréchot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action. J Hepatol 1998;29: 173-183
38. Evans AA, O'Connell AP, Pugh JC, et al. Geographic variations in viral load among Hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomark Prev 1998;7:559-565
39. Nalpas B. Alcohol and Hepatocellular Carcinoma. In: Bréchot CH (ed). Primary Liver Cancer: Etiological and progression factors. Boca Raton, FL: CRC Press, 1994, 231-245
40. Nalpas B, Pol S, Thépot V, et al. Relationship between excessive alcohol drinking and viral infections. Alcohol Alcoholism 1998;33:202-206
41. Austin H. 5, The role of tobacco use and alcohol consumption in the etiology of hepatocellular carcinoma. In: Tabor E. Di Bisceglie AM, Purcell RH (eds.) Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America. Advances in Applied Biotechnology Series, vol. 13. The Woodlands, TX: The Portfolio Publishing Company, 1991, 57-75
42. Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection. Alcohol drinking, and Hepatocellular carcinoma: A case-control study in Italy. Hepatology 1997;26:579-584
43. Trichopoulos D, Day NE, Kaklamani E, et al. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int J Cancer 1987;39:45-49
44. Kew MC, Dibisceglie AM, Paterson AC. Smoking as a risk factor in hepatocellular carcinoma. A case-control study in Southern African blacks. Cancer 1985;56:2315-2317
45. IARC monographs on the Evaluation of the carcinogenic risk of chemicals to humans. Tobacco smoking, Vol. 38. Lyon: IARC Scientific Publications. International Agency for Research on Cancer, 1986
46. La Vecchia C, Tavani A, Franceschi S, et al. Oral contraceptives and cancer. Drug Safety 1996;14:260-272
47. Kew MC, Song E, Mohammed A, et al. Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case/control study in south African Black Women. Hepatology 1990;11:298-302
48. Mant JWF, Vessey MP. Trends in mortality from primary liver cancer in England and wales 1975-92: Influence of oral contraceptives. Br J Cancer 1995;72:800-803
49. Waetjen LE, Grimes DA. Oral contraceptives and primary liver cancer: Temporal trends in three countries. Obstet Gynecol 1996;88(6):945-949
50. Bosch FX, Muños N. Prospects for epidemiological studies on hepatocellular cancer as model for assessing viral and chemical interactions. In: Bartsch H, Hemminki K, O'Neill IK (eds). Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention. Lyon: IARC Scientific Publications No. 89. International Agency for Research on Cancer, 1988, 427-437
51. Campbell TC, Chen J, Liu Ch, et al. Non association of aflaxotin with primary liver cancer in a cross-sectional ecological survey in the people's of Republic of China. Cancer Res 1990;50: 6882-6893
52. FAO, WHO, expert Comittee, JECFA and Bosch FX. Toxicological evaluation of certain food additives. WHO food additives series 37. Geneva: WHO/IPCS, 1996
53. Qian GS, Ross RK, Uy MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, Peoples's Republic of China. Cancer Epidemiol Biomark Prev 1994;3:3-10
54. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356-1359
55. Van Rensburg SJ, Cook-Mozaffari P, Van Schalkwyk DJ, et al. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer 1985:13-26
56. Hsu IC, Metcalf RA, Sun T, et al. Mutational hostpost in the p53 gene in hepatocellular carcinomas. Nature 1991;350:427-428
57. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-430
58. 1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer 1993;53:51-55
59. Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: From gene to public health. J Nat Cancer Inst 1997;89:1844-1851
60. Bannasch P, Imani Khoshkhou N, Hacker HJ, et al. Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res 1995;55:3318-3330
61. Hsing W, McLaughlin JK, Olsen JH, et al. Cancer risk following primary hemochromatosis: A population-based cohort study in Denmark. Int J Cancer 1995;60:160-162
62. Yang Q, McDonnell SM, Khoury MJ, et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: An analysis of multiple-cause mortality data. Ann Intern Med 1998;129:946-953
63. Stevens RG, Jones Y, Micozzi MS, et al. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-1052
64. Knekt P, Reunanen A, Takkunen H, et al. Body iron stores and risk of cancer. Int J Cancer 1994;56:379-382
65. Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318:1355-1362
66. McDonnell SM, Phatak PD, Felitti V, et al. Screening for hemochromatosis in primary care settings. Ann Intern Med 1998;129:962-970
67. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13:399-408
68. Bodmer JG, Parham P, Albert ED, et al. Putting a hold on "HLA-H." Nat Genet 1997;15:234-235
69. Ferra C, De Sanjosé S, Lastra CF, et al. Pentoxifyline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant 1997;20:1075-1080
70. Mandishona E, MacPhail P, Gordeuk VR, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in black africans. Hepatology 1998;27:1563-1566
71. Rivanera D, Lilli D, Griso D, et al. Hepatitis C in patients with porphyria cutanea tarda: Relationship to HCV-genotypes. New Microbiol 1998;21(4):329-334
72. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and hepatocellular carcinoma in alpha1 antitrypsin deficiency. N Engl J Med 1986;314:736-739
73. Graziadei IW, Joseph JJ, Wiesner RH, et al. Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatology 1998;28(4):1058-1063
74. Gilbert-Barness E, Barness LA, Meisner LF. Chromosomal instability in hereditary tyrosinemia type I. Pediatr Pathol 1990; 10:243-252
75. Watson HG, Ludlam CA, Rebus S, et al. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in Haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol 1992;80:514-518
76. Mauser-Bunschoten BP, Bresters D, van Drimmeten AA, et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995;45:214-246
77. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1430
78. Levine OS, Vlahov D, Nelson KE. Epidemiology of Hepatitis B virus infections among injecting drug users: Seroprevalence, risk factors, and viral interactions. Epidemiol Rev 1994;16: 418-436
79. Ghodse H, Oyefeso A, Kilpatrick B. Mortality of drug addicts in the United Kingdom 1967-1993. Int J Epidemiol 1998;27(3): 473-478
80. Goedert JJ, Pizza G, Gritti FM, et al. Mortality among drug users in the AIDS era. Int J Epidemiol 1995;24(6):1204-1210
81. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-950
82. García-Samaniego J, Soriano V, Castilla J, et al. Influence of Hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol 1997;92: 1130-1134
83. Beld M, Penning M, Lukashov V, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconvertes. Virology 1998;244(2):504-512
84. Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus coinfection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998;12(4):381-388
85. Fraumeni JF, Hoover R. Immunosurveillance and cancer: Epidemiologic observations. Epidemiology and cancer registries in the Pacific Basin. Natl Cancer Inst Monogr 1977;47:121-126
86. Gjorkander J, Cunningham-Rudles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinaemia or IgG subclass defiency. Am J Med 1988;84:107-111.
87. Bjoro K, Froland SS, Yuin Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contamined immune globulin. N Engl J Med 1994;331: 1607-1611
88. Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patient. Hepatology 1998;27:2-6
89. Ferrell LD, Wright TL, Roberts J. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992;16:865-876
90. Gunther S, Baginski S, Kissel H, et al. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology 1996;24(4):751-758
91. Gunther S, Piwon N, Iwanska A, et al. Type, prevalence and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol 1996;70(12):8318-8331
92. Hofer M, Joller-Jemelka HI, Grob PJ, et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV cohort study. Eur J Clin Microbiol Infect Dis 1998;17(1):6-13
93. Whittle HC, Maine N, Pilkington J, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995;345:1089-1092
94. Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. JAMA 1988;260:2231-2235
95. Purcell RH. 28, Prospects for prevention of Hepatitis types B and C in North America. In: Tabor E, Di Bisceglie AM, Purcell RH (eds). Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America. Advances in Applied Biotechnology Series, vol. 13. The Woodlands, TX: The Portfolio Publishing Company, 1991, 343-354
96. Szmuness W, Stevens CE, Harley EJ, et al. Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-841
97. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-1859
98. Lee Ms, Kim DH, Kim H, et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: A cohort study in Korea. Im J Epidemiol 1998;27(2):316-319
99. Gonzalez A, Esteban JI, Madoz P, et al. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial. Hepatology 1995;22:439-445
100. Hagan H, McGough JP, Thiede H, et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999;149(3):203-313
101. Hagan H, Des Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and C among participants in a syringe exchange program. Am J Public Health 1995;85:1531-1537